ProGeLife sells the first license of its anti-aging technology to Brad Pitt

Posted Oct 26, 2022, 4:02 PMUpdated Oct 26, 2022, 6:20 PM

First commercial offensive for ProGeLife created in 2014 by geneticist Nicolas Lévy, discoverer of the gene for premature aging in children affected by Progeria, and his partner Pierre Cau. And not the least: custodian of five patents, the company has just ceded the exclusive license for one of them to Brad Pitt and winemaker Marc Perrin, already associated with the American actor in the production of Château de Miraval. . The objective of this agreement is the creation of a new brand of anti-aging cosmetic care, called Le Domaine, which will be based on the active ingredients developed by the researchers.

These two are not businessmen: they want to find the funding necessary for the development of therapies neglected by “Big Pharma” in rare diseases, including Progeria, which affects a few hundred “old children” in the world. ProGeLife, which has around thirty independent shareholders, has created two subsidiaries for this purpose: Neoflow Therapeutics, dedicated to the development of targeted therapies for age-related diseases, and Calysens, which uses its commercial derivatives for the general public. .

ProGeLife has the ability to develop several plant-based molecular compositions from extracts of vine shoots, chamomile and green tea.PowerUp/Shutterstock

This operation provides for the acquisition of a minority stake in the start-up Le Domaine de l’acteur hollywoodien, accompanied by the payment of annual royalties. “This first signature should allow us to achieve between 200,000 and 300,000 euros in turnover next year. We are aiming for 3 million Ebidta margin in cosmetics in 2025”, explains Frédéric Beneton, president of ProGeLife.

Significant results

The Estate should not be its only client: its patent allows it to develop several plant-based molecular compositions derived from extracts of vine shoots, chamomile and green tea, whose synergistic effect and dosage can influence the metabolism. Mid-2023, a second cosmetics company is expected to acquire a license. Eventually, the company plans four that will take over from its fundraising totaling 3.3 million euros since its creation to finance its research.

The company relies on the result of its clinical trials conducted double-blind with placebo on a group of 60 people. “A significant statistical difference was demonstrated on the skin relief with a smoothing and anti-wrinkle effect after 56 days of application of Le Domaine fluid cream”. ProGeLife aims to market a first drug against Progeria in 2026.

What benchmarks in a constantly changing world?

Political uncertainties, scientific innovations, war in Ukraine, energy and ecological transition… How to understand these changes? How to position yourself? Every day, the 200 journalists from the “Echos” editorial staff help you decipher economic, political and international news through surveys, analyses, press reviews, chronicles and editorials. Our subscribers know that they can rely on these resources to better navigate our complex environment and make the best strategic decisions.

I discover the offers

Leave a Comment